Contra-indicated in patients with known or suspected biliary duct obstruction, or sphincter of Oddi disease or dysfunction; alcoholism, alcohol abuse, alcohol addiction, or drink more than 3 alcoholic beverages/day; a history of pancreatitis; structural diseases of the pancreas, including known or suspected pancreatic duct obstruction; severe hepatic impairment (Child-Pugh Class C); severe constipation or sequelae from constipation, or known or suspected mechanical gastrointestinal obstruction.
- TRADE NAME: Viberzi (Forest)
- INDICATIONS: Irritable bowel syndrome with diarrhea
- CLASS: Opioid mu receptor agonist
- HALF-LIFE: 4–6 hours
- FDA APPROVAL DATE: 05/27/2015
- CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:
Alfentanil, Alosetron, Anticholinergics, Atazanavir, Bupropion, Ciprofloxacin, Clarithromycin, Cyclosporine, Dihydroergotamine, Eltrombopag, Ergotamine, Fentanyl, Fluconazole, Gemfibrozil, Lopinavir, Opioids, Paroxetine Hydrochloride, Paroxetine Mesylate, Pimozide, Quinidine, Rifampin, Ritonavir, Rosuvastatin, Saquinavir, Sirolimus, Tacrolimus, Tipranavir - PREGNANCY: Insufficient evidence to inform drug-associated risk
Please login to view the rest of this drug profile.
Page last updated 07/31/2023
